[1] European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol, 2014, 60: 392-420.
[2] Bian DD, Zhou HY, Liu S, et al. Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals. Medicine (Baltimore), 2017, 96: e7885.
[3] Cunningham EB, Hajarizadeh B, Dalgard O, et al. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infect Dis, 2017, 17: 420.
[4] Lacombe K, Fontaine H, Dhiver C, et al. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort. J Acquir Immune Defic Syndr, 2017, 75: 97-107.
[5] Poordad F, Lawitz E, Gutierrez JA, et al. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep, 2017, 5: 371-375.
[6] Pugi A, Bonaiuti R, Maggini V, et al. Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database. Am J Health Syst Pharm, 2013, 70: 1039-1046.
[7] Liao H, Tan P, Zhu Z, et al. Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol, 2017, 41: 262-271.
[8] Sulkowski MS, Flamm S, Kayali Z, et al. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver Int, 2017, 37: 836-842.
[9] Alonso S, Riveiro-Barciela M, Fernandez I, et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J Viral Hepat, 2017, 24: 304-311.
[10] Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology, 2012, 143: 608-618.
[11] Rafique G, Bukhsh A, Gul A, et al. Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy. Pak J Pharm Sci, 2017, 30: 11-16.
[12] 中华医学会肝病学分会,中华医学会感染病学分会. 丙型肝炎防治指南(2015更新版). 肝脏,2015,20:933-1006. |
